News Agency
The Times

NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER

  • Written by PR Newswire
  • H002 is a precision therapeutic candidate for the treatment of NSCLC, with broad spectrum and high selectivity against multiple EGFR mutations including those with EGFR C797S mutation.
  • RedCloud Bio has initiated H002 Phase I/IIa clinical studies in both China and US.

SHANGHAI, Aug. 29, 2022 /PRNewswire/ -- RedCloud Bio (the "Company"), an...

Read more: NEXT-GENERATION EGFR TKI H002 FROM REDCLOUD BIO COMPLETES FIRST DOSE IN NON-SMALL CELL LUNG CANCER

Practical Ways to Help Reduce the Risk of Costly Business Disputes

Business disputes have a way of draining time, money and energy that could be better spent running your operation. While not every disagreement can be prevented, many disputes stem from issues that better planning may have reduced or avoided. Taking... Read more

Writers Wanted



NewsServices.com

Content & Technology Connecting Global Audiences

More Information - Less Opinion